ARTICLE | Strategy
Making Genzyme bigger
March 3, 2003 8:00 AM UTC
Although Genzyme General is due to put out its final 2002 numbers this week, the company and investors already are focused on GENZ's growth trajectory going forward. With two new products likely to come on the market this year and one that the company believes still has plenty of room to grow, GENZ should be able to triple its market cap to $15-$20 billion over the next five years.
But while it would be logical to assume that its new enzyme replacement therapies - Fabrazyme and Aldurazyme - should propel growth over the next few years, the driver for GENZ in the near term is likely to be its Renagel phosphate binder...